5.92
-0.01(-0.17%)
Currency In USD
Previous Close | 5.93 |
Open | 5.87 |
Day High | 6.02 |
Day Low | 5.54 |
52-Week High | 36.25 |
52-Week Low | 4.43 |
Volume | 2.05M |
Average Volume | 893,483 |
Market Cap | 273.67M |
PE | -2.08 |
EPS | -2.85 |
Moving Average 50 Days | 6.18 |
Moving Average 200 Days | 14.61 |
Change | -0.01 |
If you invested $1000 in 4D Molecular Therapeutics, Inc. (FDMT) since IPO date, it would be worth $146.17 as of February 05, 2025 at a share price of $5.92. Whereas If you bought $1000 worth of 4D Molecular Therapeutics, Inc. (FDMT) shares 3 years ago, it would be worth $339.45 as of February 05, 2025 at a share price of $5.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
GlobeNewswire Inc.
Jan 29, 2025 1:00 PM GMT
Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a Principal Investigator in PRISM, at Angiogenesis, Exudation, and Degeneration 2025 on Saturday, February 8,
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
GlobeNewswire Inc.
Jan 10, 2025 1:00 PM GMT
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level3E10 vg/eye demonstrated strong signals of clinical activity with sustained gain of BCVA of +8.4 lett
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
GlobeNewswire Inc.
Jan 10, 2025 1:00 PM GMT
Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosisAfter alignment with FDA and EMA on trial designs for t